NBCA/X
May 8, 2026, 06:03
Risk-Stratified HRT Use Following VTE – NBCA
NBCA shared a post on X:
“The blanket ‘no HRT after VTE’ approach is being challenged — and Dr. Cromwell is leading that conversation.
Her focus: which patient, which formulation, which risk level.
Route matters — transdermal > oral.
Thrombophilia and provocation status are critical.
Progestogen choice matters.
Hematology plus gynecology must collaborate.
Join Dr. Cromwell at NBCA’s May PEP Talk: Women and Blood Clots.
May 12 | 7 PM ET.”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience